Matches in SemOpenAlex for { <https://semopenalex.org/work/W2373093781> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2373093781 abstract "Objective To observe the hematological system adverse effects of 2 pegylated interferons(PEG-IFN) combined respectively with ribavirin in treatment of chronic hepatitis C(CHC).Methods In 171 CHC patients,140 were given PEG-IFN-2b treatment,1.5 g/kg,1/week;31 given PEG-IFN-2a,180 g,1/week.Both groups received combined rivavirin treatment,≥10.6 mg·kg-1·d-1in PEG-IFN-2b groups,and 800～1 200 mg/d,orally,in PEG-IFN-2a group,the total treatment course lasted 48 weeks.Regular follow-up was carried out to observe adverse drug effects,especially on hematological system.Results All patients completed treatment.After combined treatment,obvious adverse reaction or incidence of bone marrow suppression occurring was as following:neutropenia≤0.75×109/L was 12.87%,hemoglobin≤10 g/L was 16.96%,platelet ≤50×109/L was 12.28%.After adjustment of medication program,hemogram improved.The incidence of adverse reactions of PEG-IFN-2b group and PEG-IFN-2a as following:neutropenia ≤0.75×109/L was 12.06% vs.12.90%(P=1.000);hemoglobin ≤10 g/L was 17.02% vs.16.12%(P=0.892),platelet ≤50×109/L was 11.35% vs.16.12%(P=0.544).Adverse reaction of HCV gene 1b and 6a as following:neutropenia ≤0.75×109/L was 12.41% vs.15.38%(P=0.750);hemoglobin ≤10 g/L was 16.56% vs.19.23%(P=0.137),platelet ≤50×109/L was 11.72% vs.15.38%(P=1.000).Conclusion When PEG-IFN-2b or PEG-IFN-2a combined with ribavirin in chronic hepatitis C,there is not significant difference in incidence of adverse reaction between 2 PEG-IFNs,nor between gene types 1b and 6a,which patients can tolerate." @default.
- W2373093781 created "2016-06-24" @default.
- W2373093781 creator A5006578174 @default.
- W2373093781 creator A5012970349 @default.
- W2373093781 date "2010-01-01" @default.
- W2373093781 modified "2023-09-27" @default.
- W2373093781 title "Hematological System Adverse Reactions of Pegylated Interferon Combined with Ribavirin in Treatment of Genotype 1b and 6a Chronic Hepatitis C" @default.
- W2373093781 hasPublicationYear "2010" @default.
- W2373093781 type Work @default.
- W2373093781 sameAs 2373093781 @default.
- W2373093781 citedByCount "0" @default.
- W2373093781 crossrefType "journal-article" @default.
- W2373093781 hasAuthorship W2373093781A5006578174 @default.
- W2373093781 hasAuthorship W2373093781A5012970349 @default.
- W2373093781 hasConcept C10138342 @default.
- W2373093781 hasConcept C120665830 @default.
- W2373093781 hasConcept C121332964 @default.
- W2373093781 hasConcept C126322002 @default.
- W2373093781 hasConcept C162324750 @default.
- W2373093781 hasConcept C197934379 @default.
- W2373093781 hasConcept C203014093 @default.
- W2373093781 hasConcept C2522874641 @default.
- W2373093781 hasConcept C2776408679 @default.
- W2373093781 hasConcept C2776461080 @default.
- W2373093781 hasConcept C2776581026 @default.
- W2373093781 hasConcept C2776694085 @default.
- W2373093781 hasConcept C2777063308 @default.
- W2373093781 hasConcept C2778917026 @default.
- W2373093781 hasConcept C2780040827 @default.
- W2373093781 hasConcept C54400483 @default.
- W2373093781 hasConcept C61511704 @default.
- W2373093781 hasConcept C71924100 @default.
- W2373093781 hasConcept C89560881 @default.
- W2373093781 hasConcept C90924648 @default.
- W2373093781 hasConceptScore W2373093781C10138342 @default.
- W2373093781 hasConceptScore W2373093781C120665830 @default.
- W2373093781 hasConceptScore W2373093781C121332964 @default.
- W2373093781 hasConceptScore W2373093781C126322002 @default.
- W2373093781 hasConceptScore W2373093781C162324750 @default.
- W2373093781 hasConceptScore W2373093781C197934379 @default.
- W2373093781 hasConceptScore W2373093781C203014093 @default.
- W2373093781 hasConceptScore W2373093781C2522874641 @default.
- W2373093781 hasConceptScore W2373093781C2776408679 @default.
- W2373093781 hasConceptScore W2373093781C2776461080 @default.
- W2373093781 hasConceptScore W2373093781C2776581026 @default.
- W2373093781 hasConceptScore W2373093781C2776694085 @default.
- W2373093781 hasConceptScore W2373093781C2777063308 @default.
- W2373093781 hasConceptScore W2373093781C2778917026 @default.
- W2373093781 hasConceptScore W2373093781C2780040827 @default.
- W2373093781 hasConceptScore W2373093781C54400483 @default.
- W2373093781 hasConceptScore W2373093781C61511704 @default.
- W2373093781 hasConceptScore W2373093781C71924100 @default.
- W2373093781 hasConceptScore W2373093781C89560881 @default.
- W2373093781 hasConceptScore W2373093781C90924648 @default.
- W2373093781 hasLocation W23730937811 @default.
- W2373093781 hasOpenAccess W2373093781 @default.
- W2373093781 hasPrimaryLocation W23730937811 @default.
- W2373093781 hasRelatedWork W1966915814 @default.
- W2373093781 hasRelatedWork W1974758002 @default.
- W2373093781 hasRelatedWork W1981588917 @default.
- W2373093781 hasRelatedWork W1988025623 @default.
- W2373093781 hasRelatedWork W2007326444 @default.
- W2373093781 hasRelatedWork W2007551526 @default.
- W2373093781 hasRelatedWork W2009148769 @default.
- W2373093781 hasRelatedWork W2025788760 @default.
- W2373093781 hasRelatedWork W2029529502 @default.
- W2373093781 hasRelatedWork W2045390938 @default.
- W2373093781 hasRelatedWork W2091777474 @default.
- W2373093781 hasRelatedWork W2115184298 @default.
- W2373093781 hasRelatedWork W2147596827 @default.
- W2373093781 hasRelatedWork W2391490811 @default.
- W2373093781 hasRelatedWork W2412286968 @default.
- W2373093781 hasRelatedWork W2471333543 @default.
- W2373093781 hasRelatedWork W2498281099 @default.
- W2373093781 hasRelatedWork W3029694323 @default.
- W2373093781 hasRelatedWork W3030642393 @default.
- W2373093781 hasRelatedWork W72563251 @default.
- W2373093781 isParatext "false" @default.
- W2373093781 isRetracted "false" @default.
- W2373093781 magId "2373093781" @default.
- W2373093781 workType "article" @default.